文献速递腹部介入USCTMR

肝细胞癌放射性栓塞治疗的定量超声造影评估

Quantitative Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Radioembolization.
PubMed 文献 · Invest Radiol · 2026-07-01

这项前瞻性研究的补充分析纳入38例接受钇-90经动脉放射性栓塞(Y90-TARE)的肝细胞癌患者,在治疗后1-4小时、1周和2周进行定量超声造影(CEUS),并与治疗后2-6个月的标准横断面影像对照。结果显示,治疗后2周时无活性肿瘤与有活性肿瘤的肿瘤血管分数(FTV)存在差异(38%±24% vs 62%±28%,P=0.008),且从即刻至2周的FTV变化在两组间有统计学显著差异(41%±31% vs 11%±26%,P=0.006);其他变量在各次检查中均无显著差异(P>0.13)。结论认为定量CEUS似乎可在Y90-TARE后约2周提供治疗反应的早期指标。

要点

  • Y90-TARE后2周,无活性肿瘤FTV为38%±24%,有活性肿瘤为62%±28%(P=0.008)。
  • 从即刻至2周FTV变化:有活性肿瘤41%±31%,无活性肿瘤11%±26%(P=0.006)。
  • 灌注、峰值增强和达峰时间在各次检查中有活性与无活性肿瘤间均无显著差异(P>0.13)。

核心结论

  • 定量CEUS似乎可在Y90-TARE后约2周提供治疗反应的早期指标。

研究设计与样本

  • IRB批准的前瞻性临床试验的补充分析,最终分析纳入38例接受Y90-TARE的肝细胞癌患者。

诊断标准与关键数值

  • 以Y90-TARE后2-6个月的标准横断面CT或MRI为参考标准,由两名腹部放射科医师将肿瘤判为无活性(完全缓解)或有活性(部分缓解/疾病稳定)。
  • Y90-TARE后2周,无活性肿瘤FTV为38%±24%,有活性肿瘤FTV为62%±28%(P=0.008)。
  • 从Y90-TARE后即刻至2周,有活性肿瘤FTV变化为41%±31%,无活性肿瘤为11%±26%(P=0.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Contrast-enhanced ultrasound (CEUS) can be used to effectively monitor hepatocellular carcinoma (HCC) treatment response to percutaneous ablation and transarterial chemoembolization. Here, we performed a supplementary analysis of a prospective study to evaluate HCC participants treated with yttrium-90 transarterial radioembolization (Y90-TARE). We evaluated the utility of quantifiable parameters obtained from CEUS up to 2 weeks posttreatment for predicting treatment response compared with the standard of care cross-sectional imaging performed 2 to 6 months posttreatment (reference standard).

MATERIALS AND METHODS: In this IRB-approved, prospective clinical trial, participants with HCC scheduled for Y90-TARE underwent 3 CEUS sessions. These sessions occurred 1 to 4 hours post-Y90-TARE, 1 week, and 2 weeks posttreatment. Each CEUS examination involved a 10-minute infusion of Optison (GE HealthCare) using an Acuson Sequoia 2.0 or a HELX S3000 scanner (Siemens Healthineers) with 6C1 transducer. During each CEUS examination, flash-replenishment sequences were performed at the tumor midline for CEUS replenishment imaging. Changes between baseline and 1 or 2 weeks were used for quantitative analyses. Fractional tumor vascularity (FTV in %), perfusion (in mL/s*mg), peak enhancement (au), and time to peak (TTP in seconds) were calculated offline using Matlab (MathWorks) to quantitatively evaluate TARE response. Two abdominal radiologists read the reference standard MRI or CT obtained post-Y90-TARE and characterized the tumor as nonviable (complete response) or viable (partial response/stable disease). Unpaired t tests were performed to evaluate differences in nonviable versus viable disease. ROC analysis and logistic regression were evaluated to determine diagnostic performance and disease prediction.

RESULTS: Final analysis included 38 participants. Of these, 22 had nonviable disease (58%, 22/38) and 16 had viable disease (42%, 16/38). FTV showed a difference between nonviable and viable tumors at 2 weeks post-Y90-TARE (38% ± 24% vs 62% ± 28%, P = 0.008). In addition, there was a statistically significant difference in the change in FTV from immediately post-Y90-TARE to 2 weeks after treatment between participants with viable and nonviable disease (41% ± 31% vs 11% ± 26%, P = 0.006). No significant difference was found between viable and nonviable disease across examinations for any of the other variables ( P > 0.13).

CONCLUSIONS: Quantitative CEUS appears to provide an early indicator of treatment response ∼2 weeks post-Y90-TARE.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Wessner CE, Chong W, Berreby G, et al. Quantitative Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Radioembolization. Invest Radiol. 2026. PMID: 41178005. doi:10.1097/RLI.0000000000001255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。